SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Dabur India enters into agreements for commercialization of Ayush 64, Ayush 82

22 Feb 2016 Evaluate

Dabur India has entered into License Agreements with the government for commercialization of malaria and diabetes drug Ayush 64 and Ayush 82 respectively. Ayush-64 is an ayurvedic formulation for treatment of Malaria and while Ayush-82 is for management of diabetes.

The agreement was signed between the National Research Development Corporation (NRDC), an Enterprise of the Department of Scientific & Industrial Research, Ministry of Science & Technology and the company.

Dabur India is one of the largest FMCG Company in India. Building on a legacy of quality and experience of over 125 years, Dabur operates in key consumer products categories like Hair Care, Oral Care, Health Care, Skin Care, Home Care & Foods.



Dabur India Share Price

487.60 17.55 (3.73%)
08-May-2026 16:59 View Price Chart
Peers
Company Name CMP
Hindustan Unilever 2287.90
Godrej Consumer Prod 1042.50
Dabur India 487.60
Colgate Palmol. (I) 2196.75
P&G Hygiene 9930.50
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×